Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.
Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.
复制标题
泰国糖尿病登记项目：泰国 2 型糖尿病的血糖控制及其与降糖药使用的关系。
DOI：
--
复制
发表时间：
2006
影响因子：
--
通讯作者：
C. Komoltri
中科院分区：
文献类型：
--
作者：
N. Kosachunhanun;Y. Benjasuratwong;S. Mongkolsomlit;P. Rawdaree;N. Plengvidhya;Rattana Leelawatana;P. Bunnag;T. Pratipanawatr;S. Krittiyawong;S. Suwanwalaikorn;C. Deerochanawong;Thanya Chetthakul;C. Ngarmukos;C. Komoltri
目标
旨在确定在大学和三级医院糖尿病诊所就诊的泰国 2 型糖尿病 (T2 DM) 患者使用降糖药的模式。还分析了各种治疗方式实现的目标血糖控制效果。
材料与方法
2003 年 4 月至 12 月，对 11 家三级甲等医院和医学院的 8913 名 2 型糖尿病患者进行了横断面、以医院为基础的糖尿病登记。收集了人口统计数据、降糖药的使用情况和血糖控制水平，以确定使用模式、相关因素和血糖控制的实现情况。
结果
总体而言，2342 名 (26.3%) 的 T2 糖尿病患者的 HbA1C 低于 7%。使用二甲双胍治疗的患者比例为 70.8%，磺脲类 (SU) 为 68.7%，胰岛素为 25.3%。只有 7.0% 的患者接受了 α-葡萄糖苷酶抑制剂 (AGI)，5.7% 的患者接受了 ThaiZoliDinediones (TZD)，1.1% 的患者接受了瑞格列奈，3.2% 的患者仅接受饮食控制。仅进行饮食控制、SQU、二甲双胍、TZD、AGI、瑞格列奈和胰岛素单药治疗的患者中，分别有 57.6%、37.1%、52%、16.7%、62.5%、52% 和 16.9% 的患者实现了目标血糖控制。磺酰脲类药物是单一疗法中最常用的药物。二甲双胍与磺酰脲类药物是最常见的联合疗法，有 39.5% 的患者使用。超过 60% 接受二甲双胍单药治疗的患者体重指数 (BMI) 超过 25 kg/m2，而接受其他单药治疗的患者则不到一半。单独使用二甲双胍治疗的患者的糖尿病平均+/- SD病程为5.9 +/- 5.5年，低于接受SU治疗的患者（8.3 +/- 7.1年）和接受胰岛素治疗的患者（14.8 +/- 9.0年）。对于糖尿病病程相对较长的受试者，TDZ 通常与磺脲类药物和二甲双胍联合使用。
结论
应鼓励糖尿病患者在药物治疗中采用更好的血糖控制策略，以改善血糖控制并减少长期并发症。
OBJECTIVE
To determine the pattern of hyperglycemic agent usage in Thai type 2 diabetics (T2 DM) who attended the diabetes clinic in university and tertiary-care hospitals. The achievement oftarget glycemic control by various modalities of treatment was also analyzed.
MATERIAL AND METHOD
A cross-sectional, hospital-based diabetes registry of 8913 type 2 diabetic patients in 11 tertiary care hospitals and medical schools was carried out from April to December 2003. Demographic data, usage of hypoglycemic agents and level of glycemic control were collected to determine the pattern ofuse, associated factors, and achievement of glycemic control.
RESULTS
Overall, 2342 (26.3%) of T2 DM achieved HbA1C less than 7%. The percentage of patients treated with metformin was 70.8%, sulfonylureas (SU) was 68.7% and insulin was 25.3%. Only 7.0% of patients received alpha-Glucosidase Inhibitor (AGI), 5.7% received ThaiZoliDinediones (TZD), 1.1% received repaglinide, and 3.2% was on diet control alone. Target glycemic control was achieved in 57.6%, 37.1%, 52%, 16.7%, 62.5%, 52% and 16.9% of patients who were on diet control only, monotherapy with SQU, metformin, TZD, AGI, repaglinide and insulin,respectively. Sulfonylureas were the most commonly used drug for monotherapy. Metformin with sulfonylurea was the most common combination therapy and was used in 39.5% of patients. More than 60% of the patients treated with metformin monotherapy had body mass index (BMI) of more than 25 kg/m2, as compare to less than half of patient treated with other monotherapy agent. Mean +/- SD duration of diabetes in thepatients treated with metformin alone was 5.9 +/- 5.5 years, less than that in the SU-treated patients (8.3 +/- 7.1 years) and also in the insulin-treated patients (14.8 +/- 9.0 years). TDZ were commonly prescribed in combination with sulfonylureas and metformin in subjects with relatively longer duration of diabetes.
CONCLUSION
Better treatment strategies for glucose control ofdiabetic patients on medical treatments should be encouraged to improve glycemic control and reduce long term complications.
胰岛素和糖尿病。
DOI：
--
发表时间：
1986
期刊：
Transactions of the Association of American Physicians
影响因子：
--
作者：
Mako,ME;Rubenstein,AH
通讯作者：
Rubenstein,AH